These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 17559687

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
    Antinori A, Trotta MP, Lorenzini P, Torti C, Gianotti N, Maggiolo F, Ceccherini-Silberstein F, Nasto P, Castagna A, De Luca A, Mussini C, Andreoni M, Perno CF, GNOMO Study Group.
    Antivir Ther; 2007; 12(8):1175-83. PubMed ID: 18240858
    [Abstract] [Full Text] [Related]

  • 23. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [Abstract] [Full Text] [Related]

  • 24. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J, HIV-NAT 017 Study Team.
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM, Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, Study Team.
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [Abstract] [Full Text] [Related]

  • 33. Predictors of treatment failure during highly active antiretroviral therapy (racing trial).
    Masuhr A, Mueller M, Simon V, Zwingers T, Kurowski M, Jessen H, Lauenroth-Mai E, Moll A, Schranz D, Moecklinghoff C, Arastéh K.
    Eur J Med Res; 2002 Aug 30; 7(8):341-6. PubMed ID: 12204841
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.
    Pediatr Infect Dis J; 2006 Jun 30; 25(6):538-43. PubMed ID: 16732153
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.
    Antivir Ther; 2007 Jun 30; 12(8):1237-46. PubMed ID: 18240863
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.
    Antivir Ther; 2008 Jun 30; 13(7):927-36. PubMed ID: 19043927
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.